ATE417050T1 - Verbindungen als semaphorininhibitoren - Google Patents
Verbindungen als semaphorininhibitorenInfo
- Publication number
- ATE417050T1 ATE417050T1 AT03731824T AT03731824T ATE417050T1 AT E417050 T1 ATE417050 T1 AT E417050T1 AT 03731824 T AT03731824 T AT 03731824T AT 03731824 T AT03731824 T AT 03731824T AT E417050 T1 ATE417050 T1 AT E417050T1
- Authority
- AT
- Austria
- Prior art keywords
- compounds
- semaphorin
- independently hydrogen
- semaphorin inhibitors
- inhibitors
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 102000014105 Semaphorin Human genes 0.000 title 1
- 108050003978 Semaphorin Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000002981 neuropathic effect Effects 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
- C07D311/82—Xanthenes
- C07D311/84—Xanthenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 9
- C07D311/86—Oxygen atoms, e.g. xanthones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
- C12P17/181—Heterocyclic compounds containing oxygen atoms as the only ring heteroatoms in the condensed system, e.g. Salinomycin, Septamycin
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Psychology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pyrane Compounds (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002015216 | 2002-01-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE417050T1 true ATE417050T1 (de) | 2008-12-15 |
Family
ID=27606106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03731824T ATE417050T1 (de) | 2002-01-24 | 2003-01-22 | Verbindungen als semaphorininhibitoren |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7642362B2 (de) |
| EP (1) | EP1475382B1 (de) |
| JP (3) | JP4549675B2 (de) |
| AT (1) | ATE417050T1 (de) |
| DE (1) | DE60325172D1 (de) |
| ES (1) | ES2316763T3 (de) |
| WO (1) | WO2003062243A1 (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4820170B2 (ja) * | 2003-12-05 | 2011-11-24 | 大日本住友製薬株式会社 | 虚血性神経障害治療又は予防剤 |
| CN103379906B (zh) * | 2011-02-25 | 2016-01-20 | 学校法人庆应义塾 | 用于角膜感觉神经损伤的包含脑信号蛋白抑制剂作为活性成分的治疗剂 |
| TWI744275B (zh) * | 2016-01-15 | 2021-11-01 | 日商大日本住友製藥股份有限公司 | 2環性雜環化合物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06506202A (ja) * | 1991-03-22 | 1994-07-14 | ゼノバ リミテッド | 医薬用キサントン誘導体 |
| US5229123A (en) * | 1991-10-09 | 1993-07-20 | Hoffmann-La Roche Inc. | Antifungal agents |
| US5416197A (en) * | 1993-10-15 | 1995-05-16 | Trustees Of The University Of Pennsylvania | Antibodies which bind human collapsin |
| JP4108755B2 (ja) | 1996-09-11 | 2008-06-25 | 大日本住友製薬株式会社 | 新規セマフォリン遺伝子:セマフォリンy |
| EP0945505A4 (de) | 1996-10-09 | 2002-11-27 | Sumitomo Pharma | Neues semaphorin-gen: semaphorin w |
| WO2002009756A1 (en) | 2000-07-28 | 2002-02-07 | Sumitomo Pharmaceuticals Company, Limited | Nerve regeneration promoters containing semaphorin inhibitor as the active ingredient |
-
2003
- 2003-01-22 AT AT03731824T patent/ATE417050T1/de not_active IP Right Cessation
- 2003-01-22 DE DE60325172T patent/DE60325172D1/de not_active Expired - Lifetime
- 2003-01-22 US US10/502,453 patent/US7642362B2/en not_active Expired - Fee Related
- 2003-01-22 ES ES03731824T patent/ES2316763T3/es not_active Expired - Lifetime
- 2003-01-22 JP JP2003562120A patent/JP4549675B2/ja not_active Expired - Fee Related
- 2003-01-22 EP EP03731824A patent/EP1475382B1/de not_active Expired - Lifetime
- 2003-01-22 WO PCT/JP2003/000567 patent/WO2003062243A1/ja not_active Ceased
-
2009
- 2009-10-09 JP JP2009235580A patent/JP2010013480A/ja not_active Ceased
-
2010
- 2010-11-04 JP JP2010246965A patent/JP2011046734A/ja not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20050119334A1 (en) | 2005-06-02 |
| ES2316763T3 (es) | 2009-04-16 |
| JP2011046734A (ja) | 2011-03-10 |
| JPWO2003062243A1 (ja) | 2005-05-19 |
| EP1475382A1 (de) | 2004-11-10 |
| JP4549675B2 (ja) | 2010-09-22 |
| WO2003062243A1 (en) | 2003-07-31 |
| JP2010013480A (ja) | 2010-01-21 |
| DE60325172D1 (de) | 2009-01-22 |
| EP1475382A4 (de) | 2005-05-11 |
| EP1475382B1 (de) | 2008-12-10 |
| US7642362B2 (en) | 2010-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0610312B8 (pt) | dispositivo de assistência à caminhada | |
| MY132698A (en) | Herbicidal composition | |
| TNSN08174A1 (en) | Novel 1-aza bicycloalkyl derivatives for the treatment of psychotic and neurodegenerative disorders | |
| WO2005040116A3 (en) | Indolinone derivatives and their use in treating disease-states such as cancer | |
| MXPA05009985A (es) | Ligandos de receptores de canabinoides. | |
| BR0314688A (pt) | Novos derivados de piperidina para utilização no tratamento de estados de doença mediados pela quimiocina | |
| EP1704856A4 (de) | Proteininhibitor der hsp90-familie | |
| EP1674452A4 (de) | Neues 4-phenylaminobenzaldoximderivatie und dessen verwendung als mek-inhibitor | |
| CY1105994T1 (el) | Aναδιαταγμενες πεντανολες, μεθοδος για την παραγωγη αυτων και η χρηση αυτων ως αντιφλεγμονωδων | |
| DE60027144D1 (de) | Hydroxamsäure-derivate | |
| EP1314712A4 (de) | Substituierte benzoesäurederivate als nf-kappa-b-inhibitoren | |
| ATE278661T1 (de) | Anthranilsäurederivate | |
| DK0903347T3 (da) | Hidtil ukendte cyclodepsipeptid PF1022-derivater | |
| MXPA05006450A (es) | Nuevo derivado de 2,4-diamino-1,3,5-triazina. | |
| UA96149C2 (en) | Method for producing 4-oxoquinoline compound | |
| EP1191022A4 (de) | Neuartige dihydropyridin-derivate | |
| ATE417050T1 (de) | Verbindungen als semaphorininhibitoren | |
| IL157440A0 (en) | Triazole derivatives and pharmaceutical compositions containing the same | |
| ATE206125T1 (de) | Furoindolizine | |
| NO20051028L (no) | Substituerte tiaziner som materialbeskyttelsesmidler | |
| NO20065789L (no) | Cinnamidforbindelse | |
| NO20053208L (no) | Metode for reduktiv dehalogenering. | |
| ATE382607T1 (de) | Antitrombotische aether | |
| DK1433480T3 (da) | Lægemiddel indeholdende pyrimidin-derivat | |
| BRPI0406990A (pt) | Derivado de oligossacarìdeo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |